Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010.
Meletios A Dimopoulos, Robert Z. Orlowski, Rubén Niesvizky, Sagar Lonial, Nancy A. Brandenburg, D. Weber (2011). Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010.. , 29(15_suppl), DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.8009.
